Pro-ocular™

Clinical Trials

Demonstrated Efficacy, Safety and Adherence

Pro-ocular™ Phase 2 oGvHD Placebo Controlled Study

n=33 subjects (active:placebo, 2:1)
10-week randomized, placebo controlled then subjects remained on active treatment for the remainder of 117 weeks or 2.25 years
At week 10, placebo subjects cross-over to active drug
Conducted at Harvard University affiliated Massachusetts Eye & Ear and Dana-Farber Cancer Institute
The key Endpoints are validated, FDA-accepted

Pro-ocular™ Phase 2 Dry Eye Disease Clinical Study

Double-blind, parallel design conducted at Ora CRO (Andover, MA)
2 week study, subjects with dry eye syndrome, n=72 total
n=24 per arm (1% Pro-ocular™, 0.25% Pro-ocular™, Placebo)

U.S. Clinical Studies

In the U.S., our groundbreaking drug, Pro-ocular™, showed statistically significant promise in treating all severities of DED and other autoimmune disorders, including oGvHD and Sjogren’s syndrome.

Collaborations

Collaborations with renowned institutions such as Harvard University affiliated Massachusetts Eye and Ear and Dana-Farber Cancer Institute underscored Pro-ocular’s transformative impact, providing relief to patients suffering from ocular Graft-versus-Host Disease (oGvHD).

Patient Outcomes

Patients experienced notable pain relief, improved vision, and enhanced quality of life, with some even undergoing successful cataract surgeries after months of Pro-ocular™ treatment.

Key Data: Pro-ocular™ Phase 2 Clinical Trial

Published Study

If you’d like more information about our clinical data, get in touch today.

Pipeline

Focus on Phase 3 Clinical Trials

Novel Forehead Delivery Creates Basis for Unique Pipeline

Pro-ocular™ treats all forms of Dry eye: mild, moderate and severe.

Join Our Mission

Signal12 is raising capital to complete Phase 3 trials and bring Pro-ocular to market. Invest in a future where dry eye sufferers can enjoy lasting relief and improved vision.

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a clinical-stage dry eye company that develops novel therapies to address ophthalmic diseases. Through three Phase 2 clinical studies, the company’s proprietary topical drug, Pro-ocular™ has demonstrated efficacy in safely and effectively reducing the signs and symptoms of dry eye disease (DED). Pro-ocular™ is the first product for DED to utilize transappendageal delivery, and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. The company has offices in Greenwich, CT and Boston, MA.

Signal12 is actively raising capital to complete Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected].